Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMP-001 + Nivolumab in Refractory Melanoma
NCT04698187Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Feb 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vidutolimod in melanoma, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Confirmed Objective Response Rate at 24 months. Started Mar 2021; status: terminated.
02
Drugs
vidutolimod
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04698187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04698187.